Cholestin Red Yeast Rice Shipments Halted Pending FDA Talks
This article was originally published in The Tan Sheet
Pharmanex suspended U.S. shipments of Cholestin April 2 following a federal court decision affirming FDA's determination that the red yeast rice product is a drug, not a dietary supplement.
You may also be interested in...
FDA should consider issuing a guidance for probiotics similar to the 2004 industry guidance for botanical drugs, panelists said at a recent Drug Information Association conference
New Melilotus (yellow sweet clover) extract for "venous system" support contains coumarin, "the active ingredient in blood-thinning prescription drugs such as Coumadin," according to Swiss-based extract supplier. Linnea, which is introducing the extract to U.S. supplement market, says it has not spoken with FDA regarding whether agency might consider ingredient a "new drug." Cholestin maker Pharmanex removed red yeast rice from its products following court ruling affirming FDA's determination it contains the same active ingredient as Merck's cholesterol-lowering drug Mevacor (1"The Tan Sheet" April 9, p. 3)...
FDA is stepping up enforcement activity against red yeast rice product manufacturers and marketers in the wake of a Utah federal judge's recent decision finding the ingredient to be a drug, not a dietary supplement.